Biotech bounced back in 2013, says report


Financial services firm EY says in its annual assessment of the global biotechnology sector that the industry is performing strongly, but needs to focus on using its R&D resources more efficiently to ‘unlock value’.

Revenues, R&D spending and companies’ ability to raise capital funding all increased in 2013 compared to 2012. But the report highlights a need for the industry to be smarter about how it spends that cash. Particularly, EY decries the high failure rate of expensive Phase III clinical trials. While this observation will not surprise anyone in the industry, the report draws on case studies from across the industry to suggest some strategies that might improve efficiency.

Chief among these is not skimping on earlier trials, and designing trials to be adaptive, so they can test multiple hypotheses and reach more definitive conclusions. Other recommendations reinforce trends that are already beginning to take hold within the pharmaceutical industry: using biomarker-based diagnostics to target products more effectively at populations where they will have greatest effect, and collaborating early and often, particularly on pre-competitive problems that affect the whole sector.


Related Content

Sublime Leidenfrost

4 July 2013 Research

news image

Drop water on dry ice and a carbon dioxide layer will keep the water liquid and make it dance on (dry) ice

A drop of extra bounce

20 November 2013 Research

news image

Discovery of a way to make water bounce off surfaces faster could be used to stop ice forming on jet engines

Most Read

Sun rises on new solar route to hydrogen

27 February 2015 Research

news image

Photocatalyst has solar-to-hydrogen conversion efficiency of 2% and points way to cheap production of the gas

The mothers of invention

24 February 2015 Managing Change

news image

Nina Notman profiles four researchers successfully balancing an academic career with family life

Most Commented

Sun rises on new solar route to hydrogen

27 February 2015 Research

news image

Photocatalyst has solar-to-hydrogen conversion efficiency of 2% and points way to cheap production of the gas

Hepatitis C drug patent challenged in Europe

19 February 2015 Business

news image

Campaign group says Gilead’s expensive blockbuster sofosbuvir is not innovative enough to warrant a patent